Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12468405)

  • 1. Molecular remission and non-Hodgkin's lymphoma.
    Darby AJ; Johnson PW
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease in non-Hodgkin's lymphoma.
    Schultze JL; Gribben JG
    Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
    Moos M; Schulz R; Martin S; Benner A; Haas R
    Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Follicular (nodular) non Hodgkin's lymphoma of tonsil--case report].
    Osuch-Wójcikiewicz E; Rzepakowska A; Bruzgielewicz A; Wieczorek J
    Otolaryngol Pol; 2007; 61(2):203-6. PubMed ID: 17668812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of minimal residual disease in lymphoid malignancies.
    Brüggemann M; Pott C; Ritgen M; Kneba M
    Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma.
    Maloney DG
    Curr Opin Hematol; 1995 Jul; 2(4):255-61. PubMed ID: 9372005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
    Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C
    J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does MRD have a role in the management of iNHL?
    Giudice ID; Starza ID; Foà R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is remission in follicular lymphoma and what is its relevance?
    Buckstein R; Pennell N; Berinstein NL
    Best Pract Res Clin Haematol; 2005 Mar; 18(1):27-56. PubMed ID: 15694183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCCN: Non-Hodgkin's lymphoma.
    Zelenetz AD; Hoppe RT;
    Cancer Control; 2001; 8(6 Suppl 2):102-13. PubMed ID: 11760551
    [No Abstract]   [Full Text] [Related]  

  • 13. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
    Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.
    Narkhede MS; Cheson BD
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):447-451. PubMed ID: 29773430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods.
    Lambrechts AC; de Ruiter PE; Dorssers LC; van 't Veer MB
    Leukemia; 1992 Jan; 6(1):29-34. PubMed ID: 1736011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
    al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
    Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
    Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.